Advaxis Stock Predictions

Healthcare > Biotechnology

Buy ADXS

*Your capital is at risk

$0.604

+0 (+0%)

At Close: May 01, 2026

Currently predicting for Mon, 8 Jun 2026

ADXS Prediction Chart

ADXS Predictions History

Latest community submissions for ADXS.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
JS Pro	Apr 22, 2020	$0.608 -98.71%	$0.589	V	96.77%	1
JS Pro	Feb 18, 2020	$0.98 -98.83%	$1.05	V	93.71%	0
Steven.Ricciardi.108287	Feb 18, 2020	$1.50 -98.21%	$1.05	X	57.14%	1
JS Pro	Feb 10, 2020	$0.777 -99.09%	$1.07	V	72.62%	0
Alan Pro @Alan.115878	Feb 10, 2020	$0.80 -99.07%	$1.07	V	74.77%	0
Alan Pro @Alan.115878	Jan 21, 2020	$1.15 -98.62%	$1.04	V	89.42%	1
JS Pro	Jan 6, 2020	$1.15 -98.66%	$1.07	X	92.52%	0
SammySchillage131296	Jan 6, 2020	$3.00 -96.50%	$1.07	X	0.00%	0
T130464	Jan 2, 2020	Bearish	$1.09	V	—	0
Alan Pro @Alan.115878	Jan 2, 2020	$0.95 -98.91%	$1.09	X	87.16%	1

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for ADXS with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT ADVAXIS

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by